Your browser doesn't support javascript.
Immunogenicity of candidate SARS-CoV-2 DNA vaccines based on the spike protein.
Lim, Heeji; Kim, Se Eun; Lee, Yun Ha; Hwang, Yun-Ho; Kim, Su Hwan; Kim, Mi Young; Chung, Gyung Tae; Kim, You-Jin; Kim, Dokeun; Lee, Jung-Ah.
  • Lim H; Center for Vaccine Research, National Institute of Infectious Disease, National Institute of Health, Korea Disease Control and Prevention Agency, CheongJu, Chungcheongbuk-do, 29160, Republic of Korea.
  • Kim SE; Center for Vaccine Research, National Institute of Infectious Disease, National Institute of Health, Korea Disease Control and Prevention Agency, CheongJu, Chungcheongbuk-do, 29160, Republic of Korea.
  • Lee YH; National Institute of Health, Korea Disease Control and Prevention Agency, CheongJu, Chungcheongbuk-do, 29160, Republic of Korea.
  • Hwang YH; Center for Vaccine Research, National Institute of Infectious Disease, National Institute of Health, Korea Disease Control and Prevention Agency, CheongJu, Chungcheongbuk-do, 29160, Republic of Korea.
  • Kim SH; Center for Vaccine Research, National Institute of Infectious Disease, National Institute of Health, Korea Disease Control and Prevention Agency, CheongJu, Chungcheongbuk-do, 29160, Republic of Korea.
  • Kim MY; National Institute of Health, Korea Disease Control and Prevention Agency, CheongJu, Chungcheongbuk-do, 29160, Republic of Korea.
  • Chung GT; National Institute of Health, Korea Disease Control and Prevention Agency, CheongJu, Chungcheongbuk-do, 29160, Republic of Korea.
  • Kim YJ; Center for Vaccine Research, National Institute of Infectious Disease, National Institute of Health, Korea Disease Control and Prevention Agency, CheongJu, Chungcheongbuk-do, 29160, Republic of Korea.
  • Kim D; Center for Vaccine Research, National Institute of Infectious Disease, National Institute of Health, Korea Disease Control and Prevention Agency, CheongJu, Chungcheongbuk-do, 29160, Republic of Korea.
  • Lee JA; Center for Vaccine Research, National Institute of Infectious Disease, National Institute of Health, Korea Disease Control and Prevention Agency, CheongJu, Chungcheongbuk-do, 29160, Republic of Korea. Electronic address: jaylee1550@korea.kr.
Virology ; 573: 118-123, 2022 08.
Article in English | MEDLINE | ID: covidwho-1886125
ABSTRACT
Coronavirus disease 2019 caused by the novel human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently a major threat to public health worldwide. To deal with the needs of vaccine, we developed four DNA vaccine candidates against SARS-CoV-2, based on the full-length spike (S) or truncated S protein. Following mice vaccination, we measured T-cell response and antigen-specific neutralizing antibody (NAb) titer. All four candidates induced humoral immune responses, including elevated levels of total IgG and NAbs, and cell-mediated immune responses, including multiple cytokine expression. However, the full-length S DNA vaccine enhanced the immune responses most significantly. We then evaluated its appropriate antigen dose and vaccination schedule. Although all immunized groups showed higher immune response than the control group, inoculation with 50 µg antigen led to the highest NAb titer. Immunity was significantly increased after the third inoculation. Thus, the full-length S DNA vaccine can potentially prevent SARS-CoV-2 infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / Vaccines, DNA / COVID-19 Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Language: English Journal: Virology Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / Vaccines, DNA / COVID-19 Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Language: English Journal: Virology Year: 2022 Document Type: Article